MRNA

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Tuesday, March 26, 2024
COVID-19 vaccine, Risk, Headache, COVID-19, Ageing, Public, Vaccine, MRNA, Messenger, Chills, SARS-CoV-2, Myalgia, Clinical trial, Safety, Omicron, Fatigue

"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • "We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.
  • "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
  • In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
  • A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.

YieldMax™ ETFs Announces Monthly Distributions on MSTY (120.57%), CONY (119.30%), NVDY (106.86%), AMDY (65.04%), FBY (61.10%) and Others

Retrieved on: 
Wednesday, April 3, 2024
ARK, MSFT, COIN, Risk, History, Sale, Lovell Minnick Partners, Trust, Investment, ETF, Adviser, AAPL, Funding, TSLA, Capital gain, Prospectus, SQ, PYPL, JPM, NAV, MRNA, AI, NFLX, AMD, GOOY, Government, Unitary state, GOOGL, NVDA, TRUST, XOM, MSTR, AMZN, DIS, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Moderna, Messenger, Patient, BX, MRNA, Vaccine

Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.

Key Points: 
  • Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.
  • This landmark collaboration is another example of our long-standing strategy to partner with the world’s leading life science companies to advance their critical path vaccines, medicines and medical technologies to patients,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences.
  • Achieving this ambition requires substantial investment in late-stage studies and we are excited to welcome Blackstone and their innovative financing model.”
    This new collaboration continues Blackstone Life Sciences’ work and support for many of the world’s leading and most innovative biopharmaceutical and medical technology companies.
  • Blackstone seeks to provide customized financing solutions for companies across therapeutic areas to support mission critical scientific innovation and advance important products to patients.

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Editorial, Health, Culture, Climate change, Organization, Biotechnology, Growth, Novo Nordisk, David Berry (inventor), MIC, Pfizer, Thermo Fisher Scientific, Flagship Pioneering, MRNA, AI, Hope, Flagship, Samsung, Investment, Therapy, Most, Ecosystem, Indigo Agriculture, Multimedia, Management

CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024, ranking as the #3 most innovative company in North America. This is the third consecutive year Flagship has been named to the list, moving up two spots since 2023.

Key Points: 
  • CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024, ranking as the #3 most innovative company in North America.
  • This is the third consecutive year Flagship has been named to the list, moving up two spots since 2023.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability.

YieldMax™ ETFs Announces Monthly Distributions on NVDY (101.70%), CONY (74.88%), AIYY (70.25%), AMDY (69.08%), MRNY (66.96%) and Others

Retrieved on: 
Tuesday, March 5, 2024
ARK, NFLX, GOOY, SQ, Investment, Sale, ETF, History, Unitary state, GOOGL, Lovell Minnick Partners, JPM, Capital gain, PYPL, COIN, DIS, AAPL, MSFT, AMZN, XOM, AMD, TSLA, NVDA, TRUST, Funding, Adviser, Risk, MRNA, Prospectus, AI, NAV, Government, MSTR, Trust, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

YieldMax™ ETFs Announces Monthly Distributions on AMDY (87.93%), NFLY (78.50%), NVDY (69.23%), CONY (67.56%), FBY (61.15%) and Others

Retrieved on: 
Tuesday, February 6, 2024
ARK, Prospectus, GOOGL, Risk, Lovell Minnick Partners, NVDA, History, Government, Trust, ETF, MRNA, Investment, AAPL, Unitary state, GOOY, TRUST, AMD, Capital gain, NAV, TSLA, JPM, DIS, SQ, PYPL, COIN, Funding, Sale, Adviser, MSFT, XOM, AMZN, NFLX, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

YieldMax™ ETFs Announces Monthly Distributions on MRNY (128.16%), CONY (126.19%), AIYY (84.20%), SQY (83.05%), AMDY (79.08%) and Others

Retrieved on: 
Thursday, January 4, 2024
ARK, NAV, Risk, COIN, Capital gain, Government, AAPL, Investment, Funding, XOM, NFLX, PYPL, TSLA, GOOGL, MSFT, Lovell Minnick Partners, AMD, Trust, DIS, History, NVDA, ETF, GOOY, MRNA, Prospectus, TRUST, Adviser, JPM, Sale, AMZN, SQ, Unitary state, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

Retrieved on: 
Monday, December 11, 2023
Biophysical environment, Patient, Epidemic, Science, Partnership, Culture, Virus, Messenger, Vaccine, Access, Health, ESG, CEPI, Disclosure, Coalition, Social, MRNA, Public, Global health, Organization, Corporation, Environment

We look forward to building on our substantial ESG progress to become the best version of Moderna."

Key Points: 
  • We look forward to building on our substantial ESG progress to become the best version of Moderna."
  • Within its clinical trials, Moderna believes a committed approach to offering equal healthcare accessibility is achievable and necessary.
  • Governance & Ethics: Moderna prioritizes accountability and transparency around its ESG efforts, including through the publication of its second annual ESG report and continued commitment to disclosing key metrics.
  • To register for the live webcast of Moderna's ESG Investor Event, visit https://moderna-esg-day-2023.open-exchange.net/registration.

YieldMax™ ETFs Announces Monthly Distributions on CONY (113.67%), SQY (103.19%), TSLY (61.88%), NFLY (52.82%), MSFO (41.63%) and Others

Retrieved on: 
Wednesday, December 6, 2023
ARK, NAV, Risk, COIN, Capital gain, Government, AAPL, Investment, Funding, XOM, NFLX, PYPL, TSLA, GOOGL, MSFT, Lovell Minnick Partners, AMD, Trust, DIS, History, NVDA, ETF, GOOY, MRNA, Prospectus, TRUST, Adviser, JPM, Sale, AMZN, SQ, Unitary state, Security (finance)

For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .

Key Points: 
  • For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, NYSE, Senior, Therapy, Head, Merck & Co., Disease, Patient, Multimedia, Lung cancer, MRNA, Melanoma, Cancer, INT, MRK, NSCLC, Pharmaceutical industry, Merck

Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.

Key Points: 
  • Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.
  • “By combining KEYTRUDA with V940 (mRNA-4157), a promising new modality, we are researching innovative new approaches for earlier stage non-small cell lung cancer.”
    “Addressing lung cancer reflects the constant struggle between medical innovation and biological complexity.
  • “We believe an individualized neoantigen therapy can be this catalyst for innovation and drive us forward towards the next frontier of cancer care.
  • The companies plan to continue expansion of the comprehensive clinical development program for V940 (mRNA-4157) to additional tumor types.